Navegar por autor "Antón Aparicio, Luis Miguel"

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

2011- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; Fernández Calvo, Ovidio; [et al.]

Fructose transporter GLUT5 expression in clear renal cell carcinoma

2011- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; [et al.]

GAPDH, YWHAZ, and RRN18S as control reference genes for gene expression studies on renal cell carcinoma (RCC) formaldehyde-fixed paraffin-embedded (FFPE) tissue samples

2011- Afonso Afonso, Francisco Javier; Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Medina Villaamil, Vanessa; Fernández Calvo, Ovidio; [et al.]

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

2012- Antón Aparicio, Luis Miguel

Identification of protein expression signatures in clear renal cell carcinoma histological type

2012- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Anido Herranz, Urbano

Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients

2013- Antón Aparicio, Luis Miguel; León Mateos, Luis Ángel; Vázquez Estévez, Sergio

Metabolic syndrome (MetS) incidence in renal cell carcinoma (RCC) patients

2015- Antón Aparicio, Luis Miguel

MicroARN circulantes en sangre de pacientes con cáncer de próstata

2014- Antón Aparicio, Luis Miguel; Gómez Veiga, Francisco; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; Quindós Varela, María; [et al.]

Microrna profiling in peripheral blood predicts major response to sunitinib in metastatic renal cell carcinoma

2011- Antón Aparicio, Luis Miguel

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

2012- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; [et al.]

Molecular expression profiling and pathway analysis of formalin-fixed paraffin-embedded primary renal tumor specimens

2013- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; [et al.]

New insights into molecular mechanisms of sunitinib-associated side effects

2011- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Figueroa Conde-Valvís, Angélica; Aparicio Gallego, Guadalupe; [et al.]

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

2014- Antón Aparicio, Luis Miguel

Predictive markers in metastatic transitional cell carcinoma (mTCC) patients treated with carboplatin plus pemetrexed regimen

2013- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Real-world use of cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) PREVIOUSLY TREATED WITH DOCETAXEL: REGIONAL ANALYSIS

2015- Antón Aparicio, Luis Miguel

Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with doce

2014- Antón Aparicio, Luis Miguel

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

2014- Antón Aparicio, Luis Miguel; Castosa, R; Haz Conde, María del Mar; Rodríguez, M; Blanco Calvo, Moisés; [et al.]

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer

2013- Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; Figueroa Conde-Valvís, Angélica; García Campelo, María del Rosario; [et al.]

Searching for circulating microRNAs in genitourinary tumors

2014- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Gómez Veiga, Francisco; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; [et al.]

Repositorio digital RUNA

Navegar por autor "Antón Aparicio, Luis Miguel"

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study ﻿

Fructose transporter GLUT5 expression in clear renal cell carcinoma ﻿

GAPDH, YWHAZ, and RRN18S as control reference genes for gene expression studies on renal cell carcinoma (RCC) formaldehyde-fixed paraffin-embedded (FFPE) tissue samples ﻿

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? ﻿

Identification of protein expression signatures in clear renal cell carcinoma histological type ﻿

Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients ﻿

Metabolic syndrome (MetS) incidence in renal cell carcinoma (RCC) patients ﻿

MicroARN circulantes en sangre de pacientes con cáncer de próstata ﻿

Microrna profiling in peripheral blood predicts major response to sunitinib in metastatic renal cell carcinoma ﻿

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors ﻿

Molecular expression profiling and pathway analysis of formalin-fixed paraffin-embedded primary renal tumor specimens ﻿

New insights into molecular mechanisms of sunitinib-associated side effects ﻿

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer ﻿

Predictive markers in metastatic transitional cell carcinoma (mTCC) patients treated with carboplatin plus pemetrexed regimen ﻿

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer ﻿

Real-world use of cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) PREVIOUSLY TREATED WITH DOCETAXEL: REGIONAL ANALYSIS ﻿

Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with doce ﻿

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells ﻿

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer ﻿

Searching for circulating microRNAs in genitourinary tumors ﻿

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

Fructose transporter GLUT5 expression in clear renal cell carcinoma

GAPDH, YWHAZ, and RRN18S as control reference genes for gene expression studies on renal cell carcinoma (RCC) formaldehyde-fixed paraffin-embedded (FFPE) tissue samples

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

Identification of protein expression signatures in clear renal cell carcinoma histological type

Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients

Metabolic syndrome (MetS) incidence in renal cell carcinoma (RCC) patients

MicroARN circulantes en sangre de pacientes con cáncer de próstata

Microrna profiling in peripheral blood predicts major response to sunitinib in metastatic renal cell carcinoma

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

Molecular expression profiling and pathway analysis of formalin-fixed paraffin-embedded primary renal tumor specimens

New insights into molecular mechanisms of sunitinib-associated side effects

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

Predictive markers in metastatic transitional cell carcinoma (mTCC) patients treated with carboplatin plus pemetrexed regimen

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

Real-world use of cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) PREVIOUSLY TREATED WITH DOCETAXEL: REGIONAL ANALYSIS

Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with doce

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

Safety and efficacy of vinflunine in long-time therapy of metastatic bladder cancer

Searching for circulating microRNAs in genitourinary tumors